openPR Logo
Press release

Hemophilia Treatment Market Study 2019: Impressively growing Opportunities With Key Companies Baxalta, Baxter International, Biogen Idec,Bayer AG, CSL Behring, Chugai Pharmaceutical, Ferring B.V., Genentech

03-19-2019 03:42 PM CET | Advertising, Media Consulting, Marketing Research

Press release from: Coherent Market Insights

Hemophilia Treatment Market

Hemophilia Treatment Market

CoherentMarketInsights.com Publish a New Market Research Report On –“ Hemophilia Treatment Market 2019 Global Analysis By Key Players –Baxalta, Baxter International, Inc., Biogen Idec, Inc., Bayer AG, CSL Behring, Chugai Pharmaceutical Co., Ferring B.V., Genentech”.

High prevalence of hemophilia is propelling demand for its treatment, which is projected to drive market growth over the forecast period. According to the National Hemophilia Foundation 2018, hemophilia affected more than 400,000 individuals. Furthermore, an estimated 75% of patients suffering from hemophilia have no access to treatment or receive inadequate treatment. Moreover, according to Center for Disease Control and Prevention (CDC) report, Hemophilia A occurs in 1 out of 5,000 live male births. It is nearly four times more common than Hemophilia B. Few effective treatments available for hemophilia require lifetime infusion of expensive drugs manufactured through recombinant biotechnology or from human plasma.

Hemophilia is a genetic bleeding disorder in which an individual lacks or has low levels of proteins named clotting factors. There are around 13 types of clotting factors that work with blood platelets to help the clotting. There are three forms of hemophilia - A, B, and C. Hemophilia A is the most common form and is caused due to deficiency in factor VIII. Hemophilia B occurs due to deficiency of factor IX and Hemophilia C is caused due to factor XI deficiency. Although Hemophilia is incurable, it can be treated to reduce symptoms and avoid future health complications. Its treatment involves management of bleeding episodes, treatment and rehabilitation of hemophilia synovitis, treatment of factor VIII (FVIII) inhibitors, and prophylaxis.

The global hemophilia treatment market size was valued at US$ 9,412.1 million in 2017 and is expected to witness a robust CAGR of 4.2% over the forecast period (2018 - 2026).

Download the PDF brochure:
www.coherentmarketinsights.com/insight/request-pdf/2012

According to CDC funded randomized clinical trial, children treated on timely basis to prevent bleeding have less indication of joint damage by age of 6 years. Around 70% hemophilia patients in the U.S. receive multidisciplinary, comprehensive care in a network of federally funded hemophilia treatment centers. High-cost associated with recombinant products, serious adverse effects associated with plasma derived products, and limited access to treatment can negatively affect the growth of the global hemophilia market. For instance, risk of infectious disease transmission with plasma derived products can complicate the disease treatment.

Advancing medical knowledge and scientific research to accelerate the market growth

Rise in funding for R&D and advancement in diagnostic technology are expected to prove another booming factor for hemophilia treatment market growth. National Hemophilia Foundation (NHF) award fellowships and grants to support advanced research aimed at finding better cures and treatments for hemophilia. The organization also supports increased federal funding for research and development. Furthermore, gene therapy promises of treating genetic disorders by delivering a functional DNA copy, generally using viral vectors. Many research organizations and biotechnology companies in the gene therapy field are targeting hemophilia for development of advanced treatment options, as it can significantly reduce costs for healthcare providers and patients. Many biotechnology companies are competing to introduce the gene therapy for hemophilia. Spark Therapeutics (U.S.) and uniQure (Netherlands) have the most advanced programs so far.

The major players operating the global hemophilia treatment market include Baxalta, Baxter International, Inc., Biogen Idec, Inc., Bayer AG, CSL Behring, Chugai Pharmaceutical Co., Ferring B.V., Genentech, Inc., Hospira, Inc., Kedrion, Novo Nordisk, Octapharma AG, Pfizer, Inc., Sanofi SA, Shire Plc., and Swedish Orphan Biovitrum AB.

Get Discount On This Report:
www.coherentmarketinsights.com/insight/request-discount/2012

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

Contact Us:
Mr.Shah
Coherent Market Insights
1001 4th Ave,
#3200
Seattle, WA 98154
Tel: +1-206-701-6702
Email:sales@coherentmarketinsights.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Hemophilia Treatment Market Study 2019: Impressively growing Opportunities With Key Companies Baxalta, Baxter International, Biogen Idec,Bayer AG, CSL Behring, Chugai Pharmaceutical, Ferring B.V., Genentech here

News-ID: 1662721 • Views:

More Releases from Coherent Market Insights

Global Antihistamine Drugs Market Expected to Expand at a Steady 2024-2031 | Bayer AG, Almirall  S.A, GlaxoSmithKline, Johnson and Johnson.
Global Antihistamine Drugs Market Expected to Expand at a Steady 2024-2031 | Bay …
Coherent Market Insights introduces new research on the Global Antihistamine Drugs Market covering the micro level of analysis by competitors and key business segments (2024-2031). This report study encompasses a thorough examination of diverse segments, including opportunities, size, development, innovation, sales, and overall growth trajectory of major players. The research is carried out on primary and secondary statistical sources, providing a blend of qualitative and quantitative insights. The report also
Incretin Mimetics Market Future Business Opportunities 2024-2031 | GSK, Novo Nordisk, Lily, Haosoh, Sanofi, AstraZeneca, Pfizer Inc.
Incretin Mimetics Market Future Business Opportunities 2024-2031 | GSK, Novo Nor …
Coherent Market Insights introduces new research on the Incretin Mimetics Market covering the micro level of analysis by competitors and key business segments (2024-2031). This report study encompasses a thorough examination of diverse segments, including opportunities, size, development, innovation, sales, and overall growth trajectory of major players. The research is carried out on primary and secondary statistical sources, providing a blend of qualitative and quantitative insights. The report also focuses
Skin Rash Treatment Market Huge Growth in Future Scope 2024-2031 | AbbVie, Amgen, Bristol Myers Squibb, Galderma, Johnson & Johnson.
Skin Rash Treatment Market Huge Growth in Future Scope 2024-2031 | AbbVie, Amgen …
Coherent Market Insights introduces new research on the Skin Rash Treatment Market covering the micro level of analysis by competitors and key business segments (2024-2031). This report study encompasses a thorough examination of diverse segments, including opportunities, size, development, innovation, sales, and overall growth trajectory of major players. The research is carried out on primary and secondary statistical sources, providing a blend of qualitative and quantitative insights. The report also
Global Vitamin API Market Growth in Future Scope 2024-2031 | DSM, BASF, BOC Sciences, CSPC Pharmaceutical Group Limited.
Global Vitamin API Market Growth in Future Scope 2024-2031 | DSM, BASF, BOC Scie …
Coherent Market Insights introduces new research on the Global Vitamin API Market covering the micro level of analysis by competitors and key business segments (2024-2031). This report study encompasses a thorough examination of diverse segments, including opportunities, size, development, innovation, sales, and overall growth trajectory of major players. The research is carried out on primary and secondary statistical sources, providing a blend of qualitative and quantitative insights. The report also

All 5 Releases


More Releases for Hemophilia

Hemophilia Market
Hemophilia is an inherited genetic syndrome which impairs body-2019s capability to control blood clotting or coagulation. The episodes of bleeding mainly depend on the severity of hemophilia issue. There are two major kinds of hemophilia namely Hemophilia A & Hemophilia B. Hemophilia A is considered to be five times more prevailing as compared to hemophilia B. Occurrence of hemophilia A is found in one out of five or six thousand
Hemophilia Therapeutics Pipeline Analysis Overview
The study analysed that the hemophilia pipeline comprises of 53 drug candidates in different stages of development. The pipeline analysis based on route of administration of active drug candidates showed, that around most of the hemophilia drug candidates are being developed to be administered by intravenous route. Explore Full Report Description At@ https://www.psmarketresearch.com/market-analysis/hemophilia-therapeutics-pipeline-analysis Most of the pharma and biotech companies are developing the therapeutics for hemophilia in collaboration with educational institutes. In
Hemophilia B - Pipeline Review, H1 2017
ReportsWorldwide has announced the addition of a new report title Hemophilia B - Pipeline Review, H1 2017 to its growing collection of premium market research reports. Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia B - Pipeline Review, H1 2017, provides an overview of the Hemophilia B (Hematological Disorders) pipeline landscape. Hemophilia B is a hereditary bleeding disorder caused by a lack of blood clotting factor IX. Symptoms include
Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Koval …
ReportsWorldwide has announced the addition of a new report title Global Hemophilia Therapeutics Market By Drug (Advate, NovoSeven, Kogenate/Kovaltry, Feiba), By Type of Hemophilia (Hemophilia A, Hemophilia B), By Treatment (On-Demand, Prophylaxis), By Therapy (Replacement , Immune Tolerance Induction ) Outlook 2022 to its growing collection of premium market research reports. Hemophilia is an inherited bleeding disorder that slows the blood clotting process. The people suffering from this condition experience prolonged
In-depth analysis of the Global Hemophilia Market: hemophilia A, hemophilia B, h …
Latest industry research report on: Global Hemophilia Market | Industry Size, Share, Research, Reviews, Analysis, Strategies, Demand, Growth, Segmentation, Parameters, Forecasts Request For Sample Report @ http://www.marketresearchreports.biz/sample/sample/1064504 The hemophilia market has entered into an era of unprecedented growth rate with a variety of treatment options. Development of new therapeutics along with expansion in the current treatment options has presented new opportunities to the market. Hemophilia being an inherited genetic bleeding disorder causes
Hemophilia Treatment Drugs Market Report 2024
Global Hemophilia Treatment Drugs Market: Overview The global hemophilia treatment drugs market is presently catering to various sub-types of hemophilia such as hemophilia A, hemophilia B and others such as acquired hemophilia and hemophilia C. The increasing awareness of this disorder and the introduction of innovative ways of managing this disease has opened up several opportunities for the global market in recent years. According to the research report, the global hemophilia